BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Announces On-Track Progress for Demonstration of i/Blue Imaging System(TM)

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced continued progress towards commercial-stage manufacturing capability with Lighthouse Imaging. Per the update, the company is on target to demonstrate the i/Blue Imaging System(TM) in private meetings during the American Urology Association (“AUA”) meeting to be held in early September. The product will showcase updates to meet performance criteria against competitive products and enhancements made to the design for manufacturing. “As the process moves forward, we’re creating the potential for additional IP that will make the i/Blue Imaging System unique and innovative and strengthen the demand for blue light cystoscopy (‘BLC’),” said Jim Hutchens, Imagin’s president and CEO. “Patients have been hearing about the superiority of blue light over white light to identify bladder cancer tumors and are searching for facilities that provide it.”

To view the full press release, visit  https://ibn.fm/tnV2e

About Imagin Medical Inc.

Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The company believes its first product, the i/Blue Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The company’s initial focus is bladder cancer. Learn more at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork